AR119955A1 - METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT - Google Patents

METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT

Info

Publication number
AR119955A1
AR119955A1 ARP200102539A ARP200102539A AR119955A1 AR 119955 A1 AR119955 A1 AR 119955A1 AR P200102539 A ARP200102539 A AR P200102539A AR P200102539 A ARP200102539 A AR P200102539A AR 119955 A1 AR119955 A1 AR 119955A1
Authority
AR
Argentina
Prior art keywords
amino acid
methods
aav2
ocular neovascular
treatment
Prior art date
Application number
ARP200102539A
Other languages
Spanish (es)
Inventor
Mehdi Gasmi
Szilard Kiss
Aaron Osborne
Adam Turpcu
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of AR119955A1 publication Critical patent/AR119955A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para tratar una enfermedad neovascular ocular en un individuo, que comprenden administrar una dosis unitaria de partículas de virus adenoasociado recombinante (rAAV) al ojo del individuo, en el que las partículas de rAAV comprenden: a) un ácido nucleico que codifica un polipéptido que comprende una secuencia de aminoácidos con al menos aproximadamente un 95% de identidad con la secuencia de aminoácidos de SEQ ID Nº 35 y flanqueada por repeticiones terminales invertidas (ITR) de AAV2, y b) una proteína de la cápside de AAV2 que comprende una secuencia de aminoácidos LGETTRP (SEQ ID Nº 14) insertado entre las posiciones 587 y 588 de la proteína de la cápside, en la que la numeración de los residuos de aminoácidos corresponde a VP1 de una proteína de la cápside de AAV2.Methods of treating ocular neovascular disease in an individual are provided, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to the individual's eye, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITR), and b) an AAV2 capsid protein comprising a amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, in which the amino acid residue numbering corresponds to VP1 of an AAV2 capsid protein.

ARP200102539A 2019-09-11 2020-09-11 METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT AR119955A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962899070P 2019-09-11 2019-09-11

Publications (1)

Publication Number Publication Date
AR119955A1 true AR119955A1 (en) 2022-01-26

Family

ID=80782130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102539A AR119955A1 (en) 2019-09-11 2020-09-11 METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT

Country Status (1)

Country Link
AR (1) AR119955A1 (en)

Similar Documents

Publication Publication Date Title
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
NZ765038A (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
BR112022004027A2 (en) Methods to treat ocular neovascular diseases using aav2 variants encoding aflibercept
CL2019002474A1 (en) Vector clade f of adeno-associated virus (vaa) and related uses.
MX2021011468A (en) Recombinant adeno-associated virus vectors.
JP2020510428A5 (en)
MX2021005517A (en) Gene therapy for neuronal ceroid lipofuscinoses.
CL2020000295A1 (en) Factor viii (fviii) gene therapy methods
AR124119A2 (en) MODIFIED VIRAL PARTICLES AND THEIR USES
RU2019103488A (en) METHODS AND COMPOSITIONS FOR TREATING RDH12-RELATED DISORDERS AND DISEASES
CN112029773B (en) Nucleic acids encoding BDNF and uses thereof
RU2019126509A (en) Isolated modified protein VP1 of the capsid of adeno-associated virus serotype 5 (AAV5), capsid and vector based on it
AR041964A1 (en) HCV VACCINE UNDERSTANDING A POLINUCLEOTIDE
CO2022015313A2 (en) Variants of aav capsids and uses thereof
CL2023001876A1 (en) Viral capsid proteins with specificity for cardiac tissue cells
UY38881A (en) METHODS FOR THE TREATMENT OF EYE NEOVASCULAR DISEASES USING AFLIBERCEPT VARIANTS OF AAV2
JP2020533968A (en) Recombinant adeno-associated vector
AR119955A1 (en) METHODS OF TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT
CL2023001650A1 (en) Danon disease treatment
BR112022003206A2 (en) METHODS TO TREAT NEOVASCULAR EYE DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPTE
MX2023012410A (en) Methods of treating ocular diseases using aav2 variants encoding aflibercept.
MX2023002695A (en) Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof.
PE20241336A1 (en) MODIFIED VP1 CAPSID PROTEIN ISOLATED FROM ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED ON IT
PE20241345A1 (en) VP1 PROTEIN MODIFIED AND ISOLATED FROM THE CAPSID OF ADENOASOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON THIS